Oncology · Medical Literature
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer
Abstract
New England Journal of Medicine, Volume 395, Issue 5, Page 427-439, July 30, 2026.
Clinical relevance
In patients with HRR gene-altered metastatic castration-sensitive prostate cancer (mCSPC), does the addition of the PARP inhibitor talazoparib to enzalutamide plus androgen deprivation therapy (ADT) improve radiographic progression-free survival compared with enzalutamide plus ADT alone? __SNAPSHOT__ {"studyDesign":"Phase 3, multicenter, randomized, double-blind, placebo-controlled trial (TALAPRO-3; NCT04821622)","setting":"International, multicenter; sites across the United States, Canada, Europe, South America, and the Asia-Pacific region","sampleSize":"n=599 (talazoparib + enzalutamide: n=300; placebo + enzalutamide: n=299)","population":"Adults with histologically or cytologically confirmed prostatic adenocarcinoma (no neuroendocrine, small cell, or signet cell features), radiographically confirmed metastatic disease, ECOG PS 0–1, harboring at least one alteration in a predefined HRR12 gene panel (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) confirmed by FoundationOne or FoundationOne Liquid CDx. Approximately 35% had BRCA1/2 mutations, 71% had high-volume disease, and 84% had de novo metastatic disease. Median age was 70 years (talazoparib arm) and 69 years (placebo arm). Most common gene alterations: BRCA2 (30%), ATM (28%), CDK12 (19%), CHEK2 (15%). Prior docetaxel for mCSPC was not permitted.","intervention":"Talazoparib 0.5 mg once daily (0.35 mg if moderate renal impairment) plus enzalutamide 160 mg once daily, on a background of ongoing ADT","comparator":"Placebo plus enzalutamide 160 mg once daily, on a background of ongoing ADT","primaryOutcome":"Investigator-assessed radiographic progression-free survival (rPFS), defined as time from randomization to radiographic progression in soft tissue per RECIST v1.1 or in bone per PCWG3 criteria, or death, whichever occurred first","followUp":"Median follow-up of 37.6 months (talazoparib arm) and 37.7 months (placebo arm) for rPFS; 40.5 and 41.1 months respectively for OS interim analysis","fundingSource":"Industry (Pfizer, with enzalutamide provided by Astellas Pharma under a cost-sharing agreement)"}
Key findings
The primary endpoint was met: talazoparib plus enzalutamide produced a statistically significant and clinically meaningful improvement in investigator-assessed rPFS versus placebo plus enzalutamide. Median rPFS was not reached (95% CI, NR–NR) in the combination arm versus 45.8 months (95% CI, 37.7–NR) in the control arm (HR 0.481; 95% CI 0.357–0.647; P <0.0001), representing a 52% reduction in the risk of radiographic progression or death. The 36-month rPFS rates were 76.6% versus 56.2%, respectively — an absolute difference of 20.4 percentage points (calculated). NNT to prevent one radiographic progression or death event at 36 months = approximately 5 (calculated). In the BRCA1/2-mutated subgroup (n=104 vs. n=103), median rPFS was NR versus 35.1 months (95% CI, 18.6–NR; HR 0.368; 95% CI 0.222–0.609; P <0.0001), representing a 63% risk reduction; 36-month rPFS rates were 77.2% vs. 48.8%. In the non-BRCA HRR-altered subgroup (n=196 each arm), median rPFS was NR in both arms (HR 0.567; 95% CI 0.392–0.819; P=0.0022), representing a 43% risk reduction; 36-month rPFS rates were 76.2% vs. 60.2%. rPFS benefit was consistent across prespecified clinical subgroups including disease volume, disease stage, Gleason score, baseline PSA, ECOG PS, prior ARPI use, and geographic region. For the key secondary endpoint of overall survival (OS) — assessed at an interim analysis with median follow-up of approximately 40.5 months — median OS was not reached in either arm (HR 0.767; 95% CI 0.564–1.044; P=0.0905); 36-month OS rates were 77.8% vs. 71.6%. OS did not cross the pre-specified significance boundary, and OS data were immature. Secondary endpoints directionally favored the combination: time to PSA progression (HR 0.513; 95% CI 0.370–0.712; P <0.0001) and time to subsequent systemic antineoplastic therapy (HR 0.514; 95% CI 0.378–0.698; P <0.0001). Regarding safety: grade 3–4 treatment-emergent adverse events occurred in 79–81% of patients in the talazoparib arm versus 41–44% in the control arm. Serious adverse events were reported in 42% vs. 32% of patients. The most common adverse events (≥25%) in the combination arm were anemia, fatigue, and decreased neutrophil count. Grade 3–4 anemia occurred in 51% of patients in the talazoparib arm, with a median onset of 3.2 months; however, protocol-mandated dose reductions allowed 95% of patients to remain on talazoparib. Permanent drug discontinuation of talazoparib occurred in 19% vs. 10% in the placebo group, with anemia accounting for 5% of talazoparib discontinuations. Hematologic malignancies of special concern were reported: myelodysplastic syndrome in 3 vs. 1 patient, and acute myeloid leukemia (AML) in 2 vs. 0 patients. Venous embolic and thrombotic events occurred in 7 vs. 5 patients.
Practice implications
IMPORTANT LIMITATION: Only the published abstract and contemporaneous conference/regulatory reporting are available; the full manuscript data tables have not been independently reviewed. Conclusions are based on these sources. TALAPRO-3 establishes that talazoparib plus enzalutamide plus ADT significantly improves rPFS over enzalutamide plus ADT in HRR gene-altered mCSPC, with a clinically meaningful 52% reduction in the hazard of progression or death and an absolute 36-month rPFS difference of approximately 20 percentage points. The magnitude of benefit was greatest in BRCA1/2-mutated patients (63% risk reduction), who represent the most actionable biomarker-defined subgroup; however, statistically significant rPFS benefit was also demonstrated in the non-BRCA HRR-altered subgroup (43% risk reduction), supporting a broader HRR12-panel–defined population. Overall survival at this interim analysis did not reach statistical significance (HR 0.767; P=0.09), and OS data remain immature — a critical limitation, as OS is the gold-standard endpoint for survival benefit in this disease setting. The rPFS endpoint, while regulatory-standard, is a surrogate; whether the rPFS benefit translates into a meaningful OS benefit with longer follow-up remains to be confirmed. The trial population was heavily de novo (84%), high-volume (71%), and ECOG PS 0–1, limiting generalizability to patients with relapsed mCSPC, low-volume disease, or poor performance status. Prior docetaxel was not permitted, excluding patients who received upfront chemotherapy as part of triplet therapy. The hematologic toxicity profile is clinically significant: grade 3–4 anemia in 51% and grade 3–4 overall toxicity in ~80% of the combination arm demand proactive monitoring and dose-management protocols. The emergence of AML in 2 patients and MDS in 3 patients, though small in absolute numbers, warrants ongoing surveillance given the myelosuppressive mechanism of talazoparib. Industry sponsorship by Pfizer and Astellas represents a potential source of bias. Regulatory review (FDA Priority Review, PDUFA Q4 2026) is ongoing; talazoparib plus enzalutamide is not yet approved for the mCSPC setting. Clinicians should prioritize early and comprehensive HRR biomarker testing — using validated platforms such as FoundationOne Liquid CDx — as these results apply only to molecularly selected patients. __LIMITATIONS__ OS data are immature and did not reach statistical significance at the prespecified interim analysis threshold; the critical question of OS benefit remains unanswered and requires longer follow-up.,rPFS is a surrogate endpoint; concordance with OS has not been demonstrated in this population.,Industry sponsorship by Pfizer (manufacturer of talazoparib) and Astellas (enzalutamide) introduces potential conflicts of interest in design, analysis, and reporting.,Investigator-assessed rPFS (rather than blinded independent central review as primary analysis) may introduce ascertainment bias, though blinding was maintained.,Prior docetaxel for mCSPC was not permitted, excluding patients treated with upfront chemotherapy-based triplet regimens, limiting applicability to an increasingly common clinical scenario.,The population was predominantly de novo (84%) and high-volume (71%), limiting generalizability to oligometastatic or biochemically recurrent disease populations.,Gene-specific benefit heterogeneity within the non-BRCA HRR subgroup (ATM, CDK12, CHEK2, etc.) was not individually powered and should be interpreted with caution; benefit may not be uniform across all HRR gene alterations.,Grade 3–4 adverse events in 79–81% of the combination arm and a meaningful discontinuation rate (19%) raise tolerability concerns, particularly for older or comorbid patients not well represented in trial populations.,Rare but serious events (AML in 2 patients, MDS in 3 patients) require long-term surveillance and may not be fully captured at the current follow-up.,Only abstract-level data with conference and regulatory reporting were available for this summary; full peer-reviewed manuscript data tables and supplementary analyses have not been independently verified. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ TALAPRO-3 demonstrates that talazoparib plus enzalutamide plus ADT significantly improves rPFS (HR 0.48; P <0.0001) in HRR gene-altered mCSPC, with the strongest benefit in BRCA1/2-mutated patients, but OS remains immature and did not reach statistical significance at interim analysis. The combination carries a substantial hematologic toxicity burden (grade 3–4 AEs in ~80%; grade 3–4 anemia in 51%), requiring proactive monitoring and dose-management protocols. Early HRR biomarker testing with validated platforms is essential; pending FDA approval (Q4 2026 PDUFA date), this regimen should be considered practice-informing but not yet practice-standard outside of centers prepared for its toxicity profile and biomarker-driven patient selection.